Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Vasculitis

Update on the Management of Takayasu Arteritis

  |  

A rare form of large vessel vasculitis, Takayasu arteritis persents with no clear patterns, with patients experiencing vascular symptoms, as well as such systemic symptoms as fever and weight loss. A systematic literature review found evidence to guide rheumatologists in monitoring and treating their patients with Takayasu arteritis…

New Insights into the Management of Giant Cell Arteritis

  |  

A systematic literature review identified novel evidence on the treatment and management of GCA that was incorporated into the most recent EULAR recommendations on the management of large vessel vasculitis. Investigators confirmed the efficacy of prompt initiation of glucocorticoids and found fast-track approaches to diagnosis lowered the risk of ischemic complications…

Case Report: Possible Overlapping Vasculitis & Ulcerative Colitis

Julia Jing-ou Tan, MD, Mohammad Bardi, MD, & Natasha Dehghan, MD  |  

A 42-year-old man with a history of ulcerative colitis (UC), primary sclerosing cholangitis (PSC) and chronic sinusitis was referred to a rheumatologist to evaluate for a possible diagnosis of systemic vasculitis. This patient had developed new skin lesions, gingival hypertrophy and ulcerating tracheobronchitis, concerning for possible granulomatosis with polyangiitis (GPA). Since 1994, the patient had…

Malignancy Risk Varies with Treatment in Systemic Necrotizing Vasculitis

Reuters Staff  |  

NEW YORK (Reuters Health)—The risk of malignancy in patients with systemic necrotizing vasculitis varies according to the treatment received, according to an analysis of five randomized controlled trials. Previous studies reported an increased risk of malignancy in patients with systemic necrotizing vasculitis, and a more recent study from the European Vasculitis Study Group, based on…

ANCA Mortality: Are Patients Doing Better?

  |  

Patients with anti-neutrophil cytoplasmic antibody–associated vasculitides (AAV) have an increased risk of mortality. But treatments have evolved in recent years. Recent research found that between 1999 and 2017 the AAV mortality rate declined by nearly 2% per year in patients 65–74 years old…

Race May Not Be a Risk Factor for Giant Cell Arteritis

  |  

Past research has identified being of Northern European descent as a risk factor, among others such as age, sex and HLA DRB1, for developing giant cell arteritis (GCA). But new research casts doubts on this idea, finding that rates of biopsy proven GCA may not differ by race…

Researchers Seek the Best Methods to Maintain Remission in Vasculitis

  |  

MADRID—During the 2019 European Congress of Rheumatology (EULAR), held June 12–15, speakers addressed the complexity of vasculitis in a Challenges in Clinical Practice session titled, How to Maintain Remission in Vasculitis. Although vasculitis appears in many varieties, one commonality exists among these related yet distinct conditions: When there is vital organ or systemic involvement, disease…

Mortality from Anti-neutrophil Cytoplasmic Autoantibody-Associated Vasculitis Falling Slightly

Will Boggs, MD  |  

NEW YORK (Reuters Health)—Mortality rates in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis (AAV) decreased from 1999 to 2017, according to records from the Centers for Disease Control and Prevention (CDC). “The mortality attributed to several rare diseases [e.g., hypersensitivity pneumonitis] has increased in recent years,” Alexander W. Steinberg, MD, from Saint Joseph Hospital, Denver, tells…